These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 4988606)
41. Experimental motion sickness: efficacy of transdermal scopolamine plus ephedrine. Graybiel A; Cramer DB; Wood CD Aviat Space Environ Med; 1981 Jun; 52(6):337-9. PubMed ID: 7259691 [TBL] [Abstract][Full Text] [Related]
42. Effects of some motion sickness suppressants on static and dynamic tracking performance. Schroeder DJ; Collins WE; Elam GW Aviat Space Environ Med; 1985 Apr; 56(4):344-50. PubMed ID: 3994616 [TBL] [Abstract][Full Text] [Related]
43. Long-term office treatment of Meniere's disease. Martins JK Eye Ear Nose Throat Mon; 1969 Jul; 48(7):410-2. PubMed ID: 4978414 [No Abstract] [Full Text] [Related]
44. Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration. Graybiel A; Cramer DB; Wood CD Aviat Space Environ Med; 1982 Aug; 53(8):770-2. PubMed ID: 7181807 [TBL] [Abstract][Full Text] [Related]
45. Comparison of effectiveness of some antimotion sickness drugs using recommended and larger than recommended doses as tested in the slow rotation room. Wood CD; Graybiel A; Kennedy RS Aerosp Med; 1966 Mar; 37(3):259-62. PubMed ID: 5907763 [No Abstract] [Full Text] [Related]
46. [Evaluation of the effectiveness of drugs for prevention of motion sickness]. Galle RR; Gusakova GA; Sabaev VV; Galle NN Kosm Biol Aviakosm Med; 1988; 22(4):90-4. PubMed ID: 3066982 [No Abstract] [Full Text] [Related]
47. Effect of drugs in altering susceptibility to motion sickness in aerobatics and the slow rotation room. Deane FR; Wood CD; Graybiel A Aerosp Med; 1967 Aug; 38(8):842-5. PubMed ID: 6049246 [No Abstract] [Full Text] [Related]
48. [A new approach to the search for vestibuloprotectors]. Yasnetsov VV; Karsanova SK; Yasnetsov VV Aviakosm Ekolog Med; 2015; 49(1):5-12. PubMed ID: 25958460 [TBL] [Abstract][Full Text] [Related]
49. Méniére's disease: subjective and objective evaluation of medical treatment with betahistine HCl. Bertrand RA Acta Otolaryngol Suppl; 1972; 305():48-69. PubMed ID: 4353750 [No Abstract] [Full Text] [Related]
51. Mechanisms underlying the antimotion sickness effects of psychostimulants. Kohl RL; Lewis MR Aviat Space Environ Med; 1987 Dec; 58(12):1215-8. PubMed ID: 3322253 [TBL] [Abstract][Full Text] [Related]
52. Scopolamine alone or combined with ephedrine in seasickness: a double-blind, placebo-controlled study. Laitinen LA; Tokola O; Gothoni G; Vapaatalo H Aviat Space Environ Med; 1981 Jan; 52(1):6-10. PubMed ID: 7011299 [TBL] [Abstract][Full Text] [Related]
53. Comparison of efficacy of ginger with various antimotion sickness drugs. Wood CD; Manno JE; Wood MJ; Manno BR; Mims ME Clin Res Pr Drug Regul Aff; 1988; 6(2):129-36. PubMed ID: 11538042 [TBL] [Abstract][Full Text] [Related]
54. A study of the effect of betahistine on gastric acid secretion in man. Cochran KM; Allan JG; Russell RI Curr Med Res Opin; 1974; 2(2):63-6. PubMed ID: 4208184 [No Abstract] [Full Text] [Related]
55. Experimental assessment of selected antimotion drugs. Matsnev EI; Bodo D Aviat Space Environ Med; 1984 Apr; 55(4):281-6. PubMed ID: 6732678 [TBL] [Abstract][Full Text] [Related]
56. Theory of antimotion sickness drug mechanisms. Wood CD; Graybiel A Aerosp Med; 1972 Mar; 43(3):249-52. PubMed ID: 4402925 [No Abstract] [Full Text] [Related]
57. Metabolites of Serc and interaction of Serc with antihistamines. McKennis H Acta Otolaryngol Suppl; 1972; 305():22-8. PubMed ID: 4146949 [No Abstract] [Full Text] [Related]
58. Hope for the queasy. US Navy Med; 1976 Nov; 67(11):1-2. PubMed ID: 1076899 [No Abstract] [Full Text] [Related]
59. [The adequacy of a new method for assessing the vestibular protective effect of biologically active substances]. Karkishchenko NN; Dimitriadi NA Farmakol Toksikol; 1991; 54(5):14-6. PubMed ID: 1800137 [TBL] [Abstract][Full Text] [Related]